Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Steering the Industry through Tough Times

This article was originally published in SRA

Executive Summary

European Union member state ministers have clearly sidelined the information to patients section of the pharmaceutical package that is making its way through the European legislative process1,2. It appears that the main factor preventing its progression is an overriding concern that it could lead to direct-to-consumer advertising. The European industry has stressed that DTC advertising, which exists in the US, is something it has never wanted to be introduced. Also, it would have been prepared to have the information that it supplies vetted by an independent third party.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS114223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel